U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07275788) titled 'A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)' on Nov. 20.
Brief Summary: REGEND003, which consists of human kidney progenitor cells, demonstrates promising potential in repairing kidney injury. The purpose of this study is to assess the saftey and tolerability of REGEND003 on patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. It is an exploratory study with multi-centered, randomized, controlled, single-blinded, dose-escalated designs.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Dise...